High-Throughput Monoclonal Antibody Purification

the pharmaceutical ‘success story’ of the past decade. Mab-based pharmaceuticals command a worldwide market of more than $15 billion, and that figure will grow to exceed $30 billion by 2010. The proven safety and efficacy of Mabs as a drug class are driving faster developmental and regulatory timelines, and simplified routes from discovery to the clinic and from the clinic to the market. The dramatic growth in demand for Mabs manufactured under GMP conditions – combined with advances in upstream processes that have greatly improved the efficiency of mammalian cell culture – have focused attention on the need for advanced purification tools and platforms to enhance the speed, robustness and scalability of the downstream processes required for Mab manufacturing. In recent years, new technologies and products have been introduced that not only target key processes in Mab purification (including product harvest, capture and polishing), but also offer scalable solutions that allow for an efficient and seamless transition from the laboratory bench through to large-scale manufacturing.